12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 53.2% to $0.31 during Thursday’s after-market session. Today’s trading volume…
Beachbody, Spectrum Pharmaceuticals And This Industrial Stock Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by around 35 points on Friday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Mirati Plays Catch-Up With Amgen, Gilead’s 2nd Try With AIDS Drug, Cytokinetics’ Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
HC Wainwright & Co. Maintains Buy on Spectrum Pharmaceuticals, Lowers Price Target to $4
HC Wainwright & Co. analyst Edward White maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $6 to $4.
After FDA Rejection, Spectrum Shelves Development On Poziotinib
The FDA has granted a Complete Response Letter (CRL) to Spectrum Pharmaceuticals Inc’s (NASDAQ:SPPI) marketing application seeking approval for poziotinib…
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers LifeStance Health Gr (NASDAQ:LFST) stock increased by 37.0% to $6.89 during Friday’s pre-market session. The market value…
Expert Ratings for Spectrum Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Spectrum Pharmaceuticals (NASDAQ:SPPI) stock. These analysts…
B. Riley Securities Downgrades Spectrum Pharmaceuticals to Neutral, Lowers Price Target to $1
B. Riley Securities analyst Mayank Mamtani downgrades Spectrum Pharmaceuticals (NASDAQ:SPPI) from Buy to Neutral and lowers the price target from $1.5 to $1.
Spectrum Pharmaceuticals Q3 EPS $(0.12) Beats $(0.15) Estimate
Spectrum Pharmaceuticals (NASDAQ:SPPI) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 25 percent increase over losses of $(0.16) per share
Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know
Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.